The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Adenylosuccinate synthase, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial
The effects of obesity for the form of medicine disposition curves had been explained with all the residence period concept without having if well-mixed pockets. The imply (MDRT) and family member dis
read more..